🇺🇸 FDA
Patent

US 11548947

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11548947 (Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/57, A61P